Wu et al. established that dihydrotanshinone I can obstruct the CCL2/STAT3 signaling pathway, diminish CCL2 release from TAM and NSCLC cells, and impede the TAM recruitment capacity of NSCLC cells (136). Here, STAT3 is linked to non-small cell lung carcinoma.